Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Hospira, Inc.    

Mes dernières consult.
Most popular
Hospira, Inc. provides injectable drugs and infusion technologies.Its offers drugs, IV sets and clinical integration, infusion pumps, clinical software and implementation services.The company was founded on September 16, 2003 and is headquartered in Lake Forest, IL.  

- No events available -

More about the company
Latest news on HOSPIRA, INC.
2015 HOSPIRA : Announces First Installation of Plum 360™ Infusion System With H..
2015 HOSPIRA : Announces First Installation of Plum 360(TM) Infusion System With Hosp..
2015DJPFIZER : Buy of Hospira Gets Green Light
2015DJPFIZER : Gets U.S. Approval to Acquire Hospira, With Divestitures
2015 HOSPIRA : Expert committee BACKS Hospira’s InflectraTM
2015 HOSPIRA : Charleston Area Medical Center Integrates Smart Pump Technology to Adv..
2015 HOSPIRA : TGA Approves First mAb Biosimilar
2015 HOSPIRA : Applauds UK's NICE for Issuing Adoption Resource to Help Drive the Int..
2015DJPFIZER : Gets EU Green Light for Hospira Merger
2015 HOSPIRA : Pfizer wins EU approval for $15 billion Hospira buy
More news
Sector news : Generic Pharmaceuticals
06:18p European stocks hold firm as banks, Spanish shares fall
04:18p Smith & Nephew to buy Rotation Medical for up to $210 million
03:13pDJEuropean Corporate Roundup for Monday
02:26pDJDrug Makers Find 'Branded Generics' Are a Source for Growth
01:53p ASTRAZENECA : among backers as Swiss cancer biotech raises $200 million
More sector news : Generic Pharmaceuticals
4-Traders Strategies on HOSPIRA, INC. 
HOSPIRA, INC. - 2013
End of the technical recovery
More Strategies
News from SeekingAlpha
05/19 Upcoming Events - Panel For Epogen Biosimilar And Ocaliva's Lipid Test For Na..
2016 ABBOTT : Current Uncertainties Offer A Buying Opportunity
2016 New Management At ICU Medical Has Produced Positive Results
2016 PFIZER : 30%+ Discount With 4% Yield
2015 PREMARKET BIOTECH DIGEST : Trouble For Anticoagulants, Gilead U.S. Hep C Sales
Income Statement Evolution
F. Michael Ball Chief Executive Officer & Director
John C. Staley Non-Executive Chairman
Thomas E. Werner Chief Financial Officer & Senior Vice President
Sumant Ramachandra Chief Scientific Officer & Senior Vice President
Irving W. Bailey Lead Independent Director